Skip to content
Home/Companies/Biotech/Inozyme Pharma

Inozyme Pharma

Biotech·US·Exited 2025·Held 2yr
Entry
2023
Hold
2yr
Exit
2025

Who owns Inozyme Pharma?

Inozyme Pharma was owned by Novo Holdings through Novo Holdings Principal Investments (1999 vintage) from 2023 to 2025, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-18

Novo Holdings
Investor
Novo Holdings
Novo Holdings Principal Investments · 1999 · Buyout

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2025

More from Novo Holdings Principal Investments

Other portfolio companies in the same fund.

Tempus AI
Active
HealthTechUS· 2026
Benchmark Genetics
Active
AgTechUK· 2025
KalVista Pharmaceuticals
Active
PharmaUS· 2025
Schott Poonawalla
Active
IndustrialsIndia· 2025
Catalent
Active
PharmaUS· 2024
Manipal Hospitals
Active
HealthcareIndia· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Inozyme Pharma

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Inozyme Pharma?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Inozyme Pharma.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue